Production of Delta 9 Tetrahydrocannabinol

Abstract

The present invention provides isolated, purified Δ9 THC. In another embodiment, the invention provides pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods of preparing pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier.

1 - 50 . (canceled) 
   
   
       51 : Isolated, purified Δ9-THC consisting of about 99.3% Δ9-THC, about 0.2% cannabinol and about 0.5% other impurities. 
   
   
       52 : A pharmaceutical composition, comprising the isolated, purified Δ9-THC of  claim 51  and sesame seed oil in a soft gelatin capsule. 
   
   
       53 : Isolated Δ9-THC having a purity of at least 98% by weight. 
   
   
       54 : The isolated Δ9-THC of  claim 53  having a purity of at least 99% by weight. 
   
   
       55 : The isolated Δ9-THC of  claim 53  having a purity of at least 99.5% by weight. 
   
   
       56 : The isolated Δ9-THC of  claim 53 , comprising 0.5% or less cannabinol by weight. 
   
   
       57 : The isolated Δ9-THC of  claim 53 , comprising 0.3% or less cannabinol by weight. 
   
   
       58 : The isolated Δ9-THC of  claim 53 , comprising 0.2% or less cannabinol by weight. 
   
   
       59 : Isolated Δ9-THC having a purity of at least 95% by weight and comprising 0.2% or less by weight cannabinol. 
   
   
       60 : A method of preparing a pharmaceutical composition, comprising combining the isolated Δ9-THC of  claim 53  with a pharmaceutically acceptable carrier. 
   
   
       61 : A pharmaceutical composition, comprising the isolated Δ9-THC of  claim 53  and a pharmaceutically acceptable carrier.